Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma
Foresight Diagnostics and QIAGEN (NYSE: QGEN) have announced a strategic worldwide partnership to develop and commercialize a kit version of Foresight's CLARITY™ assay for minimal residual disease (MRD) detection in lymphoma and other blood cancers.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Positive
- Partnership combines Foresight's innovative MRD detection technology with QIAGEN's global molecular diagnostic infrastructure
- Development of the first ctDNA-based MRD assay available as both central laboratory service and diagnostic kit
- Potential expansion of QIAGEN's oncology diagnostic portfolio
- Scalable, cost-effective solution for laboratories and healthcare providers worldwide
Negative
- None.
Details
News Market Reaction – QGEN
The recorded move for QGEN in the trading session of this news was -0.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
This collaboration combines Foresight's innovative MRD detection technology with QIAGEN's global leadership in molecular diagnostic development and commercialization. Together, the companies aim to lay the groundwork for a standardized, regulated diagnostic kit that, once validated and approved in pharmaceutical-sponsored trials, would be the only circulating tumor DNA (ctDNA)-based MRD assay available as both a central laboratory service and diagnostic kit capable of supporting clinical decision-making and therapeutic strategies for patients with hematological cancers.
"We are excited to partner with QIAGEN to accelerate the development of a kit-based version of our CLARITY™ assay and expand our ability to support pharmaceutical companies in developing companion diagnostics and IVD solutions globally," said Jake Chabon, Chief Executive Officer of Foresight Diagnostics. "By combining our leading MRD technology with QIAGEN's global infrastructure and expertise, we are well-positioned to deliver a regulated diagnostic kit that has the potential to enable personalized treatment strategies for lymphoma patients worldwide."
"This new partnership represents an important step in strengthening QIAGEN's leadership in oncology by aiming to bring innovative MRD technologies into clinical practice," said Jonathan Arnold, Vice President, Head of Precision Partnering Diagnostics at QIAGEN. "By offering scalable, cost-effective solutions through the use of next-generation sequencing technology, we want to enable more laboratories and healthcare providers around the world to use MRD insights for guiding personalized treatment decisions for cancer patients."
For more information about Foresight Diagnostics and the CLARITY™ assay, visit www.foresight-dx.com.
About Foresight Diagnostics
Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. Its liquid biopsy platform, Foresight CLARITY™, is a novel assay that measures minimal residual disease (MRD) with reported detection limits in parts per million. The improved sensitivity of Foresight CLARITY™ has the potential to provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumor and hematologic malignancies. For more information, please visit foresight-dx.com and follow us on X, LinkedIn, and Bluesky. Foresight CLARITY™ IUO is an investigational device. Limited by United States Law to investigational use.
View original content to download multimedia:https://www.prnewswire.com/news-releases/foresight-diagnostics-and-qiagen-announce-strategic-partnership-to-advance-development-of-companion-diagnostic-kits-for-lymphoma-302470896.html
SOURCE Foresight Diagnostics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.